<DOC>
	<DOC>NCT00822744</DOC>
	<brief_summary>The primary objective of this study is to evaluate the efficacy of 3 fixed doses of SSR411298 (10, 50 or 200 mg daily) compared to placebo, in elderly patients with Major Depressive Disorder (MDD), based on the 17-item Hamilton Depression Rating Scale. Secondary objectives are: - To evaluate the tolerability and safety of an 8-week treatment with SSR411298 versus placebo in elderly patients with MDD. - To evaluate the effect of SSR411298 on disability, anxiety, cognitive function, sleep, pain and somatic symptoms related to depression, and bone markers. - To assess SSR411298 plasma concentrations. - To assess plasma endocannabinoid concentrations.</brief_summary>
	<brief_title>An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients</brief_title>
	<detailed_description>The study period for a participants is approximately 10 weeks including a screening up to 1 week, 8-week treatment and 1-week follow-up.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Elderly patient with recurrent Major Depressive Disorder Duration of current depressive episode greater than 2 years; Mild depression as measured by standard clinical research scales; Cognitive disturbance; Significant suicide risk; Other psychiatric conditions that would obscure the results of the study; History of failure to respond to antidepressant treatment. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Episode</keyword>
	<keyword>Antidepressant</keyword>
</DOC>